CAT-2003: A Novel Sterol Regulatory Element-Binding Protein Inhibitor That Reduces Steatohepatitis, Plasma Lipids, and Atherosclerosis in Apolipoprotein E*3-Leiden Mice

Michael Zimmer,1 Pradeep Bista,1 Ericka L. Benson,1 Diana Y. Lee,1 Feng Liu,1 Dominic Picarella,1 Rick B. Vega,1 Chi B. Vu,1 Maisy Yeager,1 Min Ding,2 Guosheng Liang,2 Jay D. Horton,2–4 Robert Kleemann,5 Teake Kooistra,5 Martine C. Morrison,5 Peter Y. Wielinga,5 Jill C. Milne,1 Michael R. Jirousek,1 and Andrew J. Nichols1

CAT-2003 is a novel conjugate of eicosapentaenoic acid (EPA) and niacin designed to be hydrolyzed by fatty acid amide hydrolase to release EPA inside cells at the endoplasmic reticulum. In cultured liver cells, CAT-2003 blocked the maturation of sterol regulatory element-binding protein (SREBP)-1 and SREBP-2 proteins and decreased the expression of multiple SREBP target genes, including HMGCR and PCSK9. Consistent with proprotein convertase subtilisin/kexin type 9 (PCSK9) reduction, both low-density lipoprotein receptor protein at the cell surface and low-density lipoprotein particle uptake were increased. In apolipoprotein E*3-Leiden mice fed a cholesterol-containing western diet, CAT-2003 decreased hepatic inflammation and steatosis as evidenced by fewer inflammatory cell aggregates in histopathologic sections, decreased nuclear factor kappa B activity in liver lysates, reduced inflammatory gene expression, reduced intrapathic choleseterol ester and triglyceride levels, and decreased liver mass. Plasma PCSK9 was reduced and hepatic low-density lipoprotein receptor protein expression was increased; plasma cholesterol and triglyceride levels were lowered. Aortic root segments showed reduction of several atherosclerotic markers, including lesion size, number, and severity. CAT-2003, when dosed in combination with atorvastatin, further lowered plasma cholesterol levels and decreased hepatic expression of SREBP target genes. Conclusion: SREBP inhibition is a promising new strategy for the prevention and treatment of diseases associated with abnormal lipid metabolism, such as atherosclerosis and nonalcoholic steatohepatitis. (Hepatology Communications 2017;1:311–325)

Introduction

CAT-2003 is a novel conjugate of eicosapentaenoic acid (EPA) and niacin that is cleaved intracellularly into its active components through the activity of fatty acid amide hydrolase (FAAH), an endoplasmic reticulum (ER)-resident enzyme responsible for the catabolism of several bioactive fatty acid amides.1,2 The requirement for intracellular enzymatic cleavage ensures the codelivery of both EPA and niacin moieties into the cell. Cleavage of CAT-2003 by FAAH has been demonstrated by using liver homogenates with and without a selective FAAH inhibitor and with a recombinant FAAH enzyme.2 Omega-3 fatty acids, such as EPA and docosahexaenoic acid, inhibit sterol regulatory element-binding

Abbreviations: APOE, apolipoprotein E; AUC, area under the curve; EPA, eicosapentaenoic acid; ER, endoplasmic reticulum; FAAH, fatty acid amide hydrolase; GPR109A, G-protein coupled receptor 109A; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; Insig-1, insulin induced gene 1; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; LPS, lipopolysaccharide; mRNA, messenger RNA; NASH, nonalcoholic steatohepatitis; NF-kB, nuclear factor kappa B; PCSK9, proprotein convertase subtilisin/kexin type 9; PNPLA3, patatin-like phospholipase domain containing 3; SCAP, SREBP cleavage-activating protein; SREBP, sterol regulatory element-binding protein; VLDL, very low-density lipoprotein; WTD, C, western diet plus cholesterol.

Received January 25, 2017; accepted April 11, 2017.
Additional Supporting Information may be found at onlineibrary.wiley.com/doi/10.1002/hep4.1042/suppinfo.
protein-1 (SREBP-1). They also reduce inflammation through inhibition of nuclear factor kappa B (NF-κB) activity. CAT-2003 inhibits SREBP better than EPA alone in cell-culture experiments. SREBP consists of three isoforms, SREBP-1a, SREBP-1c, and SREBP-2, that regulate intracellular cholesterol and lipid levels by promoting the transcription of genes required for their synthesis. SREBP is synthesized as a transcriptionally inactive precursor molecule that is retained in the ER through its interaction with SREBP cleavage-activating protein (SCAP) and insulin-induced gene (Insig) proteins. Under cholesterol-limiting conditions, SREBP is transported to the Golgi where the mature N-terminal domain is released to enter the nucleus and promote the transcription of genes involved with cholesterol and fatty acid synthesis. SREBP also regulates genes involved with cholesterol transport and clearance, including LDLR and PCSK9. Low-density lipoprotein receptor (LDLR) regulates plasma LDL cholesterol (LDL-C) levels by internalizing LDL particles, whereas secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDLR at the cell surface to promote its internalization and degradation. Niacin is actively transported into HepG2 cells and primary hepatocytes and may enhance delivery of EPA to the liver.

Niacin favorably impacts serum lipoproteins, increasing high-density lipoprotein (HDL)-C while decreasing LDL-C and triglycerides. It also causes subcutaneous skin flushing, and the degree to which these activities are separable is controversial. Flushing is the result of extracellular niacin binding to G-protein coupled receptor 109A (GPR109A) on islet of Langerhans cells, whereas niacin binding to GPR109A in adipose tissue inhibits lipolysis and blocks the release of free fatty acids. This deprives the liver of substrate for the generation of triglycerides and is thought to be a major contributor to niacin’s effects on lipid lowering. Indeed, one study showed that niacin failed to lower both free fatty acid and triglyceride levels in GPR109A knockout mice. However, GPR109A-independent effects of niacin have also been reported, including enhanced degradation of de novo apolipoprotein B protein in the liver, which is required for liver very-low-density lipoprotein (VLDL) secretion, and decreased diglyceride acyltransferase activity. Another study in GPR109A-deficient mice found that niacin decreased LDL-C and triglycerides despite a lack of effect on adipose tissue. CAT-2003 neither activated GPR109A in a human epidermal cell line nor promoted skin flushing in a phase 1 study. Thus, the niacin moiety of CAT-2003, in addition to facilitating liver uptake, would exert only GPR109A-independent effects on lipid lowering.

The APOE*3-Leiden mouse is a well-established model for the study of cardiovascular and metabolic diseases. These mice express the dominantly inherited APOE*3-Leiden mutation as a trans gene as well as human APOC1. The primary effect of the APOE*3 mutation is impaired clearance of triglyceride-rich lipoproteins.
lipoproteins due to decreased affinity for LDLR, while lipolysis is inhibited due to overexpression of APOC1. Impaired clearance leads to high LDL-C levels and a more human-like fast protein liquid chromatography cholesterol profile. These animals, when fed a high-fat and high-cholesterol Western diet (WTD+C) for 16 weeks, develop dyslipidemic disease burden, including atherosclerotic lesions in the aortic root, fatty liver, and inflammation. The inflammation induced by increased hepatic triglyceride and cholesterol may help promote the morbidity of hypercholesterolemia and hepatic steatosis. This model therefore has important implications for studying and understanding fatty liver-related diseases, such as nonalcoholic steatohepatitis (NASH), even though the animals do not develop the pronounced fibrosis associated with NASH.

Materials and Methods

CELL CULTURE AND REAGENTS

HepG2 (HB-8065) cell lines were obtained from ATCC. RAW264 and 7-3X NF-κB cells have been reported. Cells were maintained in Dulbecco’s modified Eagle’s medium (11965; Invitrogen) supplemented with 10% fetal bovine serum (10437; Invitrogen). The LANCE Ultra cAMP kit was obtained from Perkin Elmer (TRF0262). Bovine serum albumin was obtained from Sigma (A7030). AlamarBlue was obtained from Invitrogen (DAL1100). Atorvastatin was obtained from Sigma.

WESTERN BLOT ANALYSIS

For HuH-7 cell experiments, whole-cell lysates were prepared and subjected to immunoblot analyses of SREBP-1 and SREBP-2 as described. For HepG2 experiments, cells were lysed in radio immunoprecipitation assay buffer with protease and phosphatase inhibitors. Densitometry was performed relative to actin in matched lanes. Goat anti-human SREBP-2 antibody was from R&D Systems (AF7119). LDLR antibody was from BioVision (3839-100). Beta-actin antibody was from Abcam (Ab8226). Secondary antibodies were from Li-Cor.

ENZYME-LINKED IMMUNOSSORBANT ASSAYS

HepG2 cells were treated in triplicate with the indicated concentrations of EPA, niacin, the combination of EPA + niacin, or CAT-2003, and secreted PCSK9 was measured in the supernatant 6 hours or 16 hours later using commercially available enzyme-linked immunosorbent assay kits (DPC900; R&D Systems). Plasma levels of E-selectin (R&D Systems), PCSK9 (CY-8079; Circulex), serum amyloid A (Biosource), and soluble vascular cell adhesion molecule 1 (R&D Systems) were determined by enzyme-linked immunosorbent assay.

RNA ISOLATION AND SEMIQUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION

Total RNA was collected using RNeasy Plus Mini kit (74136; Qiagen) and complementary DNA generated using SuperScriptIII (18080-044; Invitrogen) with random hexamers following the manufacturer’s protocol. Relative messenger RNA (mRNA) expression levels were determined using TaqMan probes (Applied Biosystems, using recommended best primer pairs) with HPRT as the internal control.

NF-κB REPORTER ASSAY

RAW264.7-3X NF-κB cells were treated with compound for 2 hours. Lipopolysaccharide (LPS; final concentration 250 ng/mL) and AlamarBlue viability reagent were then added, and cells were incubated for an additional 3 hours. Cell viability was determined by measuring the AlamarBlue fluorescence (excitation = 550 nm, emission = 590 nm) on the Victor 5 plate reader. To assess NF-κB reporter activity, the supernatant was removed from the cells from each well and Bright Lite Plus luciferase reagent (6066761; Perkin Elmer) was added to each well. The luciferase signal was measured in counts per second on the Victor 5 plate reader.

p65 DNA BINDING ASSAY

NF-κB activity was assessed by measuring p65 activity in liver homogenates. Whole-cell lysates were prepared, and total protein concentrations were measured using a bicinchoninic acid protein assay (Thermo Scientific Pierce). NF-κB activity was measured using an NF-κB p65 Transcription Factor kit (Thermo Scientific Pierce). Equal volumes of whole-cell lysates were loaded, and results were then normalized to the

313
amount of protein loaded as determined by the bicinchoninic acid assay.

**HYDROXYPROLINE ASSAY**

Paraffin-embedded liver tissues were subjected to acid hydrolysis for 20 hours at 95°C. Hydroxyproline was measured in the hydrolysate using a total collagen assay relative to a collagen standard per the manufacturer’s instructions (Quickzyme, Leiden, the Netherlands).

**LDL UPTAKE AND CELL-SURFACE LDLR IMAGING**

The LDL uptake assay was performed according to the manufacturer’s protocol. Briefly, culture medium was replaced with LDL-Dylight 550 working solution and incubated at 37°C for 4 hours, washed once with phosphate-buffered saline, and then LDL uptake was determined under the microscope by measuring excitation and emission wavelengths of 540 and 570 nm, respectively. Following the LDL uptake measurement, cells were fixed but not permeabilized to ascertain cell-surface LDLR expression, using rabbit anti-LDL receptor primary and Dylight 488-conjugated secondary antibodies. The slides were mounted with Antifade with 4’,6-diamidino-2-phenylindole. Cell staining was examined using a Zeiss LSM 510 confocal microscope with a 25× objective lens. Images were collected with five slices of Z-stack (2-μm interval), and three such image stacks were collected from each slide chamber. The quantitative data of LDL uptake and LDLR staining were analyzed using ImageJ.

**ANIMAL STUDIES**

All animal studies conformed to the rules and regulations set forward by the Netherlands Law on Animal Experiments and were approved by the Committee on Animal Experiments (approval number 3138). APOE*3-Leiden mice were generated using a cosmid vector containing APOE*3-Leiden and APOC1 genes, and the region between the APOC1 and APOC1 pseudogene, injected into fertilized eggs of (C57Bl/6J × CBA/J)F1 mice. The transgenic strain was established by breeding founder mice with C57Bl/6J mice.(22) The WTD+C diet consisted of 40.5% sucrose, 20% casein, 15% cocoa butter, 10% corn starch, 5.45% cellulose, 5.1% mineral mixture, 1% choline chloride, 1% corn oil, 0.2% methionine, and 1% cholesterol, supplemented or not with 0.75% (weight/weight) CAT-2003. All diets received 30 mg/kg alpha tocopherol to prevent potential oxidation of CAT-2003. In a separate study with male C57BL/6 mice fed the same diet for 7 days, significant exposure levels of CAT-2003, as determined by its linker-niacin metabolite, were measured in both plasma (area under the curve [AUC]last 32,414 ± 1,680 hour × ng/mL) and liver (AUClast 46,247 ± 3,387 hour × ng/mL). For the atherosclerotic endpoint study, female APOE*3-Leiden mice were matched in groups (n = 16) based on plasma cholesterol levels after a 4-week run-in period on the WTD+C diet. The study continued for 16 weeks with animals on control WTD+C or 0.75% CAT-2003 diets, with plasma taken at weeks 0, 2, 4, 12, and 16 before sacrificing for end of study atherosclerosis and liver histology measurements. For the atorvastatin study, female APOE*3-Leiden mice were treated similarly except that after the 4-week WTD+C run-in period, animals were switched to WTD+C diets containing atorvastatin (dosed as a diet admixture that has historically produced plasma levels equivalent to a 20-mg/kg dose), 0.75% CAT-2003, or the combination of atorvastatin and CAT-2003 (n = 10). Animals were killed and livers flash frozen for mRNA and protein analysis after 4 weeks of dosing.

**PLASMA MEASUREMENTS**

Triglycerides were measured using either Cayman Chemicals (10010303) or Roche Diagnostics (11488872) kits. Cholesterol was measured using Abcam (ab65390) or Roche Diagnostics (11489437) kits. Lipoprotein profiles were determined in pooled plasma, fractionated using an ÄKTA fast protein liquid chromatography system (Pharmacia, Roosendaal, the Netherlands), and analysed as reported.(26)

**ATHEROSCLEROTIC ENDPOINT MEASUREMENTS**

Serial cross-sections (5 μm thick) were taken throughout the entire aortic root area for histological analysis of atherosclerosis as described.(27) Briefly, paraffin-embedded aortic cross-sections were stained with hematoxylin-phloxine-saffron, and the atherosclerotic lesion area was analyzed blindly in four cross-sections of each specimen (at intervals of 50 μm). Cell-D software (Olympus Soft Imagine Solutions GmbH)
was used for morphometric computer-assisted quantification of lesion number, lesion area, and lesion severity according to the classification of the American Heart Association.\(^{25}\)

**LIVER HISTOPATHOLOGY**

Liver pathology was evaluated as described.\(^{28}\) Briefly, NASH development was assessed in hematoxylin and eosin-stained liver sections (3 μM) by analysis of steatosis and inflammation, the two key features of NASH. Steatosis was determined at a 40× magnification by analysis of macrovesicular and microvesicular steatosis and hepatocellular hypertrophy (hepatocyte size > 1.5 × normal diameter), expressed as the percent of the total liver slice area affected (considering only the area of the slice occupied by hepatocytes). Hepatic inflammation was analyzed by counting the number of inflammatory foci per field at a 100× magnification (view size 3.1 mm\(^2\)) in five different fields per specimen and was expressed as the average number of foci per field. Liver sections were also assessed for collagen by Sirius-Red staining and macrophage content using rat anti-mouse monoclonal F4/80, clone BM8 from Thermo Fisher/eBioscience (14-4801-81).

**STATISTICAL ANALYSIS**

For parameters with multiple measurements (plasma cholesterol and triglycerides), two-way analysis of variance was used with the factors time and treatment. For in vitro studies and atherosclerosis endpoint values, group comparison \(P\) values were determined using the Student \(t\) test. Data sets that were not normally distributed (Shapiro-Wilk test) were tested with the non-parametric Mann-Whitney U test. Unless stated otherwise, data are shown as means ± SEM. \(P < 0.05\) was considered significant using the following scale: \(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.\)

**Results**

**CAT-2003 INHIBITS SREBP MATURATION AND DECREASES SREBP-MEDIATED GENE EXPRESSION**

We tested CAT-2003 for effects on SREBP processing in HuH-7 cells (Fig. 1A). An equal concentration of arachidonic acid blocked the processing of SREBP-1 without affecting SREBP-2, consistent with previous findings.\(^{4,5}\) The inhibition of SREBP-1 and SREBP-2 by CAT-2003 was greater than that of 1 μg/mL 25-hydroxycholesterol, which potently inhibits SREBP processing by trapping SCAP in the ER (Fig. 1A).\(^{29}\) Consistent with these data, CAT-2003 decreased the expression of multiple SREBP target genes in a dose-dependent manner (Fig. 1B). Relative expressions of archetypal SREBP target genes \(PCSK9, HMGCR,\) and \(LDLR\) are shown in Fig. 1B. However, similar results were obtained for other SREBP target genes, including \(FASN, SCD1, PNPLA3, ACC2, INSIG1, SREBP1,\) and \(SREBP2\) (data not shown).

**CAT-2003 INCREASES LDLR PROTEIN EXPRESSION**

The inhibition of \(LDLR\) and \(PCSK9\) mRNAs promote opposing forces on LDLR protein expression, concomitantly decreasing its synthesis while increasing its stability. We therefore tested for the effect of CAT-2003 on LDLR protein expression in HepG2 cells. We found that LDLR protein expression was increased in a dose-dependent manner by CAT-2003 treatment, while the combination of niacin and EPA had no effect (Fig. 2A). The increase in LDLR expression was more pronounced for the nascent low molecular weight form of the protein than it was for the mature glycosylated form. CAT-2003 decreased secreted PCSK9 protein levels, while the combination of niacin and EPA had no effect (Fig. 2B). To confirm that LDLR is increased at the cell surface, we determined cell-surface LDLR expression and the ability to internalize labeled LDL particles in CAT-2003-treated HepG2 cells by confocal microscopy. LDLR protein expression was determined in fixed but non-permeabilized cells. We found that CAT-2003 increased cell surface LDLR protein expression and incorporation of labeled LDL particles by ~20% (Fig. 2C). HepG2 cells tend to grow as clumps, and it is sometimes hard to determine cellular architecture. 4',6-diamidino-2-phenylindole costained and z-stack images underscore that the observed LDLR staining was predominantly localized to the cell surface (Supporting Fig. S1).

**CAT-2003 INHIBITS INFLAMMATORY MARKERS**

Because omega-3 fatty acids are known to be anti-inflammatory, we tested CAT-2003 for inhibition of
LPS-induced expression of the *IL1β* and *TNF*α genes in the human monocytic cell line THP-1. We found that CAT-2003 decreased the levels of both of these markers/mediators of inflammation, while equivalent concentrations of EPA and niacin added separately or in combination did not (Supporting Fig. S2A,B). Moreover, we found that CAT-2003 inhibited LPS-induced NF-κB reporter activity in RAW 264.7 macrophages stably expressing an NF-κB-luciferase transgene.\(^{30}\) No inhibition was observed when equivalent concentrations of EPA and niacin, alone or in combination, were tested in the same assay (Supporting Fig. S2C).

### CAT-2003 DECREASES PLASMA CHOLESTEROL AND TRIGLYCERIDE LEVELS

APOE*3-Leiden mice were fed the WTD+C diet for 4 weeks. CAT-2003 was then administered for an additional 16 weeks as a 0.75% diet admixture. CAT-2003 lowered PCSK9, total cholesterol, and triglyceride levels within 2 weeks of treatment, and the levels were significantly and stably decreased by ~30% within 4 weeks of treatment (Fig. 3A-C). After 16 weeks, a full cholesterol fast protein liquid
chromatography profile was performed. The majority of the cholesterol decrease was from the VLDL and LDL fractions, while HDL levels were comparatively unchanged (Fig. 3D).

Flash-frozen liver samples were homogenized and analyzed for LDLR protein expression by western blotting. We found that liver LDLR protein levels doubled in CAT-2003-treated animals relative to control mice. The increase in LDLR protein was inversely proportional to the change in plasma PCSK9 (Fig. 3E). Systemic inflammation was also decreased in CAT-2003-treated animals as measured by decreases in plasma expression serum amyloid-A and soluble vascular cell adhesion molecule 1 (Fig. 3F).

CAT-2003 PREVENTS FORMATION OF ATHEROSCLEROTIC LESIONS

CAT-2003 treatment significantly decreased the total lesion area and number in aortic root segments. It
also increased the number of undiseased segments (Fig. 4A). A representative hematoxylin phloxine saffron stained photomicrograph demonstrating the decreased lesion area is shown in Supporting Fig. S3A. These differences led to a redistribution of the lesion severity such that fewer animals exhibited the severe type 5 phenotype (Fig. 4B). Macrophage-mediated degradation of the fibrous cap contributes to atherosclerotic plaque instability. Treatment with CAT-2003 increased plaque stability as determined by increased collagen content and reduced macrophage infiltration (Fig. 4C). Representative photomicrographs demonstrating reduced collagen staining, as analyzed by Sirius-Red staining, and reduced...
CAT-2003 REDUCES DIET-INDUCED FATTY LIVER AND FIBROSIS

Liver sections were examined by histopathology. Representative photomicrographs of the hematoxylin staining as well as the Oil-Red-O staining are illustrated in Supporting Fig. S3B,C. Treatment with CAT-2003 also significantly reduced liver weights relative to control animals (Fig. 5E) and were similar to age-matched animals fed a normal diet (data not shown).
Significant decreases for macrovesicular steatosis, microvesicular steatosis, and hypertrophy inflammatory cell aggregates were observed in livers of CAT-2003-treated animals (Fig. 6A). Representative photomicrographs showing reduced inflammatory foci and macrophage infiltration are shown in Supporting Fig. S4A, B. NF-κB DNA binding and Il1β and TNfα mRNA expression were decreased in liver homogenates (Fig. 6B). CAT-2003 also reduced liver collagen deposition as determined by hydroxyproline assay (Fig. 6A). Liver sections of CAT-2003-treated animals similarly showed reduced Sirius-Red staining for collagen (Supporting Fig. 4C).

CAT-2003 SHOWS ADDITIVE CHOLESTEROL LOWERING ACTIVITY WHEN DOSED WITH ATORVASTATIN

We next tested CAT-2003 in combination with atorvastatin in vitro and in vivo. Treatment of HepG2 cells with atorvastatin increased SREBP-2 processing to its mature nuclear form and increased PCSK9 mRNA expression and PCSK9 protein secretion. CAT-2003 decreased the amount of mature SREBP-2 protein and attenuated the atorvastatin-induced increase in PCSK9 mRNA and PCSK9 protein secretion (Supporting Fig. S5).

We therefore conducted a 4-week APOE*3-Leiden mouse study to test the effects of co-administering CAT-2003 with atorvastatin. CAT-2003 and atorvastatin, when dosed as single agents, significantly reduced plasma cholesterol relative to control animals at both 2 and 4 weeks of treatment. The combination of CAT-2003 and atorvastatin decreased cholesterol even further (46.5% versus 19.7% with CAT-2003 alone and 13.8% for atorvastatin alone), indicating that CAT-2003 works additively with a atorvastatin (Fig. 7A). This decrease was significant relative to control and CAT-2003-only- and atorvastatin-only-treated animals. Cholesterol in the control group increased 8.1% (Fig. 7B). Similar to our first study (Fig. 5E), the WTD+C diet led to increased liver weight relative to normal diet control animals. Atorvastatin had no effect on liver weight gain, but the livers in CAT-2003-treated animals, when dosed alone or in combination with atorvastatin, were comparable to those in normal diet control animals (Fig. 7C).

Plasma PCSK9 levels were decreased in CAT-2003 and CAT-2003 plus atorvastatin–fed animals, while atorvastatin alone showed no significant change (Fig. 7D). Liver Pcsk9 gene expression was also decreased by CAT-2003 (Fig. 7E). LDLR protein was increased in the liver homogenates of the CAT-2003-fed and combination-fed animals as measured by western blot (Fig. 7F). Similar to Psk9, the expression of SREBP target genes Hmgcr, Acc2, and Scd1 were decreased in the CAT-2003 and combination diet groups but unchanged in the atorvastatin-only group (Fig. 8A-C).

Discussion

Omega-3 and other polyunsaturated fatty acids have been shown to inhibit SREBP-1 (3-5) but have little...
effect on SREBP-2. CAT-2003, however, potently inhibits both isoforms. To the best of our knowledge, it is the only molecule known to do so. We believe this is because FAAH, the enzyme that cleaves EPA from the niacin moiety, is an ER-resident enzyme. This serves to concentrate the EPA in the ER membrane.

When the EPA of CAT-2003 was switched to the fluorescent fatty acid cis-parinaric acid, it was observed that the modified conjugate had an ER-like perinuclear pattern, whereas cis-parinaric acid by itself was highly concentrated in lysosomes. Pre-incubation with an endocytosis inhibitor blocked the ER cellular

**FIG. 6.** CAT-2003 inhibits hepatic steatosis and inflammation in APOE*3-Leiden mice. (A) macrovesicular steatosis, microvesicular steatosis, hepatocellular hypertrophy, and inflammation, as measured by histopathology in H&E sections, and hydroxyproline measurement for collagen in livers from control or CAT-2003-fed animals after 16 weeks. (B) NF-κB DNA-binding activity, *I*IIβ mRNA and *T*nfα mRNA expression as measured by real-time reverse-transcription polymerase chain reaction in 16-week liver samples. Significance analysis for liver histopathology analysis in panel A was determined by the nonparametric Mann-Whitney U test. Significance for hydroxyproline measurement in panel B was determined by the Student *t* test. Values are expressed as mean ± SEM (n = 16). Abbreviation: H&E, hematoxylin and eosin. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
localization, suggesting that unlike the free fatty acid the conjugated cis-parinaric acid enters the cell by active endocytosis via clathrin-coated vesicles.\(^2\) We hypothesize that this allows freed EPA to bind to a lipophilic site that stabilizes the SREBP/SCAP/Insig complex in the ER. SREBP-2 inhibition apparently requires a higher concentration of EPA than SREBP-1, as nuclear SREBP-1 is completely inhibited after 2 hours with CAT-2003 treatment while nuclear SREBP-2 is only partially inhibited at the same time point (Fig. 1A). SREBP-2 inhibition by omega-3 fatty acids may only be achievable through enhanced ER delivery.

Statins are direct 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors, blocking the de novo synthesis of cholesterol.\(^{32}\) This activates SREBP and promotes the synthesis of LDLR, which enhances the clearance of plasma lipoproteins; however, it also up-regulates PCSK9, which promotes LDLR degradation.\(^{33,34}\) Thus, the efficacy of statins is self-limiting and determined through the establishment of a new steady state that represents the net effect of opposing factors. Pharmacologic SREBP inhibition potentiates the effect of atorvastatin by establishing yet a new steady state. This likely occurs through down-regulation of HMGCR mRNA expression, which would compound inhibition of de novo cholesterol synthesis, and by blocking the statin-induced up-regulation of PCSK9. However, SREBP inhibition also decreases LDLR mRNA synthesis, which would limit the improvement of CAT-2003 when used with a statin. Use of alirocumab or evolocumab, which are humanized monoclonal antibodies against PCSK9 that have significant LDL-C lowering effects, represents an alternative choice for combination therapy as they would specifically block the PCSK9 effect of SREBP up-regulation while maintaining the increased expression of LDLR mRNA.\(^{35,36}\) However, these agents would not inhibit HMGCR mRNA expression. Moreover, while these agents potentiate the efficacy of statins, they do not replicate the intrahepatic effects of SREBP inhibition. Alirocumab, which cross-reacts with mouse PCSK9, dose dependently decreased plasma cholesterol and triglycerides in APOE*3-Leiden. CTEP mice through up-regulation of LDLR, but had no effect on hepatic cholesterol or triglyceride content.\(^{37}\)
As with statin therapy, the effect of CAT-2003 when used as a single agent on plasma cholesterol is the result of a new steady state that represents the net effect of opposing forces. In the APOE*3-Leiden mice, the balance of these opposing forces favors improved plasma lipids. However, it is possible that the relative strengths of these opposing forces will vary across different species or even within heterogeneous populations of the same species. This may explain the relatively modest effects of CAT-2003 for lowering PCSK9, non-HDL-C, and LDL-C in early clinical studies.\(^\text{(20)}\)

A limitation in our study is an inability to parse the relative contribution of the EPA or niacin moiety on the observed changes in plasma lipids. The intracellular delivery of EPA and niacin cannot be mimicked by co-administration of the individual components as is evidenced by our in vitro assays. Moreover, altering the components of the conjugate is also problematic in that the EPA moiety is needed for FAAH-dependent cleavage and intracellular delivery of the EPA and niacin and the niacin moiety is required for enhanced liver uptake of the conjugate. However, the fact that non-HDL-C was selectively decreased suggests a contribution of the niacin beyond enhancing liver delivery. While neither CAT-2003 nor its linker-niacin metabolite binds GPR109A, we cannot rule out that the linker niacin or the parent compound might be acting extracellularly via another cell-surface receptor.

The reduction of diet-induced hepatic steatosis and liver inflammation suggests that SREBP inhibition may be efficacious in treatment of NASH. Given the inherent self-limiting effects of CAT-2003 on plasma lipids, this may be the best use for pharmacologic SREBP inhibition. APOE*3-Leiden mice fed a high-cholesterol diet for 20 weeks develop overt NASH with fibrosis.\(^\text{(38)}\) While fibrosis was only beginning to occur at the shorter experimental period used in our study, we could nevertheless detect a decrease in collagen content in the livers of CAT-2003-fed animals relative to controls. Approximately 1 in 3 Americans have some degree of hepatic steatosis,\(^\text{(39)}\) which is the first stage of NASH. Hepatic steatosis is asymptomatic and can resolve itself through changes in diet; however, a subset of these patients will progress to NASH, which affects 2%-5% of Americans. NASH is characterized as fatty liver with inflammation and damage. At some point in its progression, the liver becomes fibrotic and cirrhosis develops. NASH is a growing worldwide problem, particularly in areas with high hepatitis C or human immunodeficiency virus infection rates.\(^\text{(40)}\) In addition to cirrhosis, patients are at increased risk of developing hepatocellular carcinoma.\(^\text{(41)}\) SREBP inhibition could improve NASH through decreased FASN expression, an SREBP target gene that is the rate-limiting step in de novo fatty acid synthesis, and reduced hepatic inflammation. SREBP inhibition may also help clear liver fat through increased \(\beta\)-oxidation of fatty acids. This could occur.

![Graphs showing the reduction of SREBP target gene expression in livers of APOE*3-Leiden mice.](image-url)

**FIG. 8.** CAT-2003 reduces SREBP target gene expression in livers of APOE*3-Leiden mice. (A) Hmgcr, (B) Acc2, and (C) Scd1 normalized mRNA (to housekeeping gene transcript, Hprt) expression following 4 weeks of treatment. Significance was determined by the Student \(t\) test. Values are expressed as mean ± SEM \((n = 10)\). \(*p < 0.05\), \(**p < 0.01\), \(***p < 0.001\), \(****p < 0.0001\).
through inhibition of acetyl-coenzyme A carboxylase-2, which is responsible for the formation of malonyl-coenzyme A, which inhibits the transport of fatty acids into the mitochondrial matrix through inhibition of carnitine palmitoyltransferase 1. (42)

A polymorphism in the SREBP-2 gene, SREBF-2, predisposes individuals to NASH. (43) Moreover, a variant of the PNPLA3 gene, PNPLA3 I148M, is strongly associated with NASH (44) and is an SREBP target gene. (45) Patatin-like phospholipase domain-containing 3 (PNPLA3) is inhibited by CAT-2003 in vitro (data not shown). The polymorphism occurs in 45% of Hispanics, 33% of Caucasians, and 24% of African Americans. (46) Interestingly, Pnpla3 knockout mice do not develop fatty liver (47); rather, the predisposition toward NASH is associated with the PNPLA3 I148M variant accumulating on lipid droplets. (48)

We have recently shown that CAT-2003 reduces fibrosis, inflammation, and preneoplastic lesions in a murine NASH model. (49) Interestingly, niacin itself has been reported to reduce hepatic steatosis in rats fed a high-fat diet. However, this effect was attributed to the GPR109A-dependent decrease in free fatty acids from adipose tissue reducing triglycerides in the liver, and no effect was seen on SREBP target genes in this study. (50) Thus, we believe that the effects observed for hepatic steatosis with CAT-2003 in our study are the result of EPA-mediated inhibition of SREBP.

In summary, CAT-2003 is a novel conjugate of EPA and niacin, designed to be taken up by the liver and release EPA at the ER. It inhibits the maturation of both SREBP isoforms and dose-dependently decreases the expression of SREBP target genes. In APOE*3-Leiden mice, CAT-2003 lowers plasma triglyceride and cholesterol levels, improves multiple atherosclerotic endpoints, and works additively when dosed in combination with atorvastatin. It also decreased the steatosis, inflammation, and fibrosis that occur in the livers of these mice when fed a WTD+C diet. These data suggest that SREBP inhibition may be useful for the treatment of dyslipidemia and NASH.

Acknowledgment: We thank Wim van Duyvenvoorde, Karin Toet, and Erik Offerman at the Netherlands Organization for Applied Scientific Research for technical assistance and the entire Catabasis team for numerous discussions and help in the preparation of this manuscript.

REFERENCES

1) Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilola NB. Molecular characterization of an enzyme that degrades neuroendometrial fatty-acid amidases. Nature 1996;384:83-87.
2) Vu CB, Benis JE, Benson E, Bista P, Carney D, Fahnner R, et al. Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid. J Med Chem 2016;59:1217-1231.
3) Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polymersaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-1539.
4) Tanaka N, Zhang X, Sugiyama E, Kono H, Horiuchi A, Nakajima T, et al. Eicosapentaenoic acid improves hepatic steatosis independent of PPARalpha activation through inhibition of SREBP-1 maturation in mice. Biochem Pharmacol 2010;80:1601-1612.
5) Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem 2001;276:4365-4372.
6) Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142:687-698.
7) Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 2002;30:1091-1095.
8) Brown MS, Goldstein JL. Cholesterol feedback from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009;50 Suppl:S15-27.
9) Sun LP, Li L, Goldstein JL, Brown MS. Inisig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J Biol Chem 2005;280:26483-26490.
10) DeBose-Boyd RA, Brown MS, Li WP, Nothurft A, Goldstein JL, Espenshade PJ. Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 1999;99:703-712.
11) Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50 Suppl:S172-177.
12) Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116:2995-3005.
13) Said HM, Nabokina SM, Balamurugan K, Mohammed ZM, Urbina C, Kashyap ML. Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. Am J Physiol Cell Physiol 2007;293:C1773-1778.
14) Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem 2003;14:298-305.
15) Goel H, Dunbar RL. Niacin alternatives for dyslipidemia: fool's gold or gold mine? Part II: Novel niacin mimetics. Curr Atheroscler Rep 2016;18:17.
16) Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. PUMA-G and HM74 are receptors for nicotinic acid and apolipoprotein B (ApoB) and VLDL secretion from mouse hepatocytes. FASEB J 2011;25:B174.
17) Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-1845.
Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1042/suppinfo.

Author names in bold designate shared co-first authorship.